Most Recent
The gender pay gap remains a sore spot for IP boutiques and one major US-based litigation firm, according to data released by the Workplace Gender Equality Agency.
Bayer and Teva have lost their challenge to Indian drug maker Cipla’s extension of its patent for an allergy medication, with IP Australia finding a failure to pay renewal fees on time was due to a genuine error.
The start-up behind Hungry Jack's plant-based 'Rebel Whopper' wants a court to review IP Australia's decision that a proposed patent covering its fake meat product didn't pass muster.
V2food, the CSIRO-backed start-up behind Hungry Jack's plant-based 'Rebel Whopper', has lost its bid to patent a product that changes colour when cooked in order to imitate the “meat experience”.
German drug maker Merck KGaA is fighting US drug company Merck Sharp & Dohme over the alleged use of the ‘Merck’ mark in Australia, five years after their intellectual property spat was settled.
The CSIRO has successfully appealed a decision that blocked the government agency’s application to patent a method of producing high-fibre wheat.
Johnson & Johnson-owned Janssen has secured an injunction against drug maker Juno Pharmaceuticals, halting the release of Juno's generic version of schizophrenia drug Invega Sustenna.
Biotech Regeneron and drug company Bayer have resolved their appeal of a ruling that allowed generic pharmaceutical manufacturer Sandoz to launch a version of top selling macular degeneration drug Eylea.
After losing a fight over access to millions of seized documents, Fortescue has settled its trade secrets case against green iron company Element Zero.
Andrew ‘Twiggy’ Forrest’s Fortescue can't get access to nine million seized documents in its trade secrets spat against green iron start-up Element Zero.